“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps
Allergy · 2025
DOI: 10.1111/all.70151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von P E Vonk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Antibodies, Monoclonal, Humanized, Sinusitis. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Dupilumab is effective in treating patients with type‐2 dominant chronic rhinosinusitis with nasal polyps (T2‐CRSwNP). Dosing starts at an interval of 1×/2 weeks (Q2W) with possible tapering upon disease control. Prolonging the interdose interval reduces patient burden and side effects and improves cost‐effectiveness.
Objectives
(1) Analyze how many patients successfully reach and maintain extended tapering of at least 1×/12 weeks (Q12W), (2) evaluate differences in baseline characteristics and clinical measurements between patients who maintain disease control on ≥ Q12W (“super‐responders”) and patients who do not; (3) compare characteristics of “super‐responders” to patients reaching Q12W but losing disease control on that dose (“excellent responders”).
Method
Prospective cohort study including dupilumab‐treated T2‐CRSwNP patients with a minimum follow‐up of 2.5 years.
Results
From a total of 198 patients, 28 (14%) were “super‐responders”, and 26 (13%) “excellent responders.” “super‐responders” had less comorbid asthma (60.7% vs. 85.9%, p < 0.001), lower baseline immunoglobulin E levels (median [Q1: Q3]: 145 [58.7; 485] vs. 313 [135.5; 746]; p = 0.007) and a shorter time since last sinus surgery (2.5 years [1; 4.8] vs. 4 years [2; 7]; p = 0.026) compared to others. No differences were observed between “excellent” and “super‐responders” at baseline, nor at the start of the Q12W interval. “excellent responders” showed worsening of clinical outcomes as well as increases in T2 markers in blood between start and stop of the Q12W interval.
Conclusion
Tapering of dupilumab to once every 12 weeks (Q12W) can be applied to super‐responding patients. No clear predisposing factors were identified predicting the feasibility of extended tapering.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
ORCID-Profile: J J Otten, H B E Elzinga, S Reitsma
Zitieren
APA
Vonk, P. E., Otten, J. J., Elzinga, H. B. E., van der Lans, R. J. L., Adriaensen, G. F. J. P., Benoist, L. B. L., Hoven, D. R., Fokkens, W. J., Reitsma, S., & PolyREG Consortium (2025). “Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps. Allergy. https://doi.org/10.1111/all.70151
Vancouver
Vonk PE, Otten JJ, Elzinga HBE, van der Lans RJL, Adriaensen GFJP, Benoist LBL, et al. “Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps. Allergy. 2025. doi:10.1111/all.70151
BibTeX
@article{Vonk2025,
author = {Vonk, P E and Otten, J J and Elzinga, H B E and van der Lans, R J L and Adriaensen, G F J P and Benoist, L B L and Hoven, D R and Fokkens, W J and Reitsma, S and PolyREG Consortium, PolyREG Consortium},
title = {“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.70151}
}
EUVIMED